Frequently Asked Questions

  • The exact mechanism for the treatment of moderate to severe cellulite is unknown.1 QWO is believed to initiate a process we call Enzymatic Subcision and Remodeling (ESR™).2 Read more about ESR here.

  • At Day 71, both the physicians and patients were asked independently to assess the appearance of cellulite in each buttock on a photonumeric cellulite severity scale, or PCSS.13 The primary efficacy endpoint was defined as the proportion of patients who had a two-level improvement in both the physician and patient PCSS scores in the target buttock at Day 71 in the intent to treat (ITT) population.1 A two-level improvement means that a patient improved from severe to mild or moderate to almost none on the cellulite severity scale, and this was the primary endpoint of the study.1,13 To put it in context, both the patient rating and the physician rating had to agree on at least a two-level improvement.1 The improvement had to be in the target buttock, which was randomly assigned at the beginning of the trial.3,11

  • In clinical trials, 84% of subjects treated with QWO experienced injection site bruising.1 In the Phase 3 clinical studies, there was no correlation between the severity of bruising and pain. Bruising decreased with each round of treatment.14 Generally, adverse reactions had a duration of less than 21 days.1 Read more about AEs here.

  • Yes, a patient needs to complete all three sessions to see results. While independent assessments may vary, QWO was studied in patients who received three sets of injections spaced 21 days apart.1 Efficacy results were assessed at Day 71.1

Looking for more information?

Additional information can be found in our clinical education center.


Qwo® is indicated for the treatment of moderate to severe cellulite in the buttocks of adult women.

Important Safety Information for QWO


QWO is contraindicated in patients with a history of hypersensitivity to collagenase or to any of the excipients or the presence of infection at the injection sites.

Warnings and Precautions

Hypersensitivity Reactions

Serious hypersensitivity reactions including anaphylaxis have been reported with the use of collagenase clostridium histolyticum. If such a reaction occurs, further injection of QWO should be discontinued and appropriate medical therapy immediately instituted. Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions.

Injection Site Bruising

In clinical trials, 84% of subjects treated with QWO experienced injection site bruising. Subjects with coagulation disorders or using anticoagulant or antiplatelet medications (except those taking ≤150 mg aspirin daily) were excluded from participating in Trials 1 and 2.

QWO should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet (except those taking ≤150 mg aspirin daily) or anticoagulant therapy.

Substitution of Collagenase Products

QWO must not be substituted with other injectable collagenase products.

QWO is not intended for the treatment of Peyronie’s Disease or Dupuytren’s Contracture.

Adverse Reactions

In clinical trials, the most commonly reported adverse reactions in patients treated with QWO with an incidence ≥ 10% were at the injection site: bruising, pain, nodule and pruritus.

View Full Prescribing Information for QWO.